about
Mass spectrometry based identification of geometric isomers during metabolic stability study of a new cytotoxic sulfonamide derivatives supported by quantitative structure-retention relationshipsAdvances in structure elucidation of small molecules using mass spectrometryDealing with the unknown: metabolomics and metabolite atlases.High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites.Direct-EI in LC-MS: towards a universal detector for small-molecule applications.Differentiation of regioisomeric aromatic ketocarboxylic acids by positive mode atmospheric pressure chemical ionization collision-activated dissociation tandem mass spectrometry in a linear quadrupole ion trap mass spectrometer.An overview of matrix effects in liquid chromatography-mass spectrometry.Identification of lipophilic bioproduct portfolio from bioreactor samples of extreme halophilic archaea with HPLC-MS/MS.New derivatization strategies for the ultrasensitive analysis of non-aromatic analytes with APLI-TOF-MS.Data-dependent neutral gain MS3: toward automated identification of the N-oxide functional group in drug metabolites.Simultaneous screening of glutathione and cyanide adducts using precursor ion and neutral loss scans-dependent product ion spectral acquisition and data mining tools.Turbulent flow chromatography in bioanalysis: a review.A facile and sensitive method for quantification of cyclic nucleotide monophosphates in mammalian organs: basal levels of eight cNMPs and identification of 2',3'-cIMP.Quantitative LC-MS/MS Analysis of Proteins Involved in Metastasis of Breast Cancer.Regiospecificity of human UDP-glucuronosyltransferase isoforms in chalcone and flavanone glucuronidation determined by metal complexation and tandem mass spectrometry.SILEC: a protocol for generating and using isotopically labeled coenzyme A mass spectrometry standardsTargeted proteomics by selected reaction monitoring mass spectrometry: applications to systems biology and biomarker discovery.Database searching for structural identification of metabolites in complex biofluids for mass spectrometry-based metabonomics.From known knowns to known unknowns: predicting in vivo drug metabolites.NMR spectroscopy as a tool to close the gap on metabolite characterization under MIST.Metabolite identification by mass spectrometry: forty years of evolution.Drug metabolite profiling and identification by high-resolution mass spectrometry.Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry.Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?Accelerator MS: its role as a frontline bioanalytical technique.Chemical derivatization as a tool for optimizing MS response in sensitive LC-MS/MS bioanalysis and its role in pharmacokinetic studies.Recent advances in metabolite identification and quantitative bioanalysis by LC-Q-TOF MS.The current status of clinical proteomics and the use of MRM and MRM(3) for biomarker validation.The application of quantification techniques in proteomics for biomedical research.Biotransformation and biocatalysis: roles and applications in the discovery of antimalarials.An introduction to hybrid ion trap/time-of-flight mass spectrometry coupled with liquid chromatography applied to drug metabolism studies.New trends in the analytical determination of emerging contaminants and their transformation products in environmental waters.Glucuronides from metabolites to medicines: a survey of the in vivo generation, chemical synthesis and properties of glucuronides.Mass spectrometry and NMR spectroscopy: modern high-end detectors for high resolution separation techniques--state of the art in natural product HPLC-MS, HPLC-NMR, and CE-MS hyphenations.The current state-of-the-art in the determination of pharmaceutical residues in environmental matrices using hyphenated techniques.Applications of mass spectrometry in drug metabolism: 50 years of progress.A high-resolution accurate mass (HR/AM) approach to identification, profiling and characterization of in vitro nefazodone metabolites using a hybrid quadrupole Orbitrap (Q-Exactive).Preparation of labeled human drug metabolites and drug-drug interaction-probes with fungal peroxygenases.Application of high-resolution MS for development of peptide and large-molecule drug candidates.One drop chemical derivatization--DESI-MS analysis for metabolite structure identification.
P2860
Q28539290-6901A5AE-8C79-45CD-94E8-0698FBA04EEBQ28743720-D66B06B2-CC4F-4B64-A05A-04A3753CD611Q33349044-044DF941-630B-4C9C-8683-BA80239B04ACQ33439410-36AF116D-84D1-49CC-A813-682F5D1C7AA7Q33449684-311081F4-D92F-47C7-8094-AFCE5C5A3643Q33450060-FDC9B43F-185C-4045-81FD-AC3F5DD00C90Q33450184-ECC13E3A-A3E2-4E83-A816-B8877C920B53Q33460761-15C25873-FF95-482A-88BB-CBD9C70292D7Q33465662-D258E7F4-FD33-47F4-8BDD-A1E5840D729EQ33530771-32E6C1E0-180A-4C5B-A834-D8D295D069CDQ34185397-6F030BA1-A531-4ABF-8661-9044A8B56541Q34317104-FD99019E-BDBF-4660-BD66-19C84F967F90Q34785800-250319A0-EF3A-4414-8A82-DCB92CFF74DFQ35692228-09438500-D92D-4531-B343-B5E4CB00E437Q37010122-C015BDDA-1C54-4D50-9433-F9FF01BB2A9CQ37242476-B2C9AB42-9798-496B-874A-6A533A7BAC42Q37803137-1EB5AA8D-A474-472D-84CF-5BB2A759112AQ37810165-825AAC83-078E-4CEA-9EFF-CC593F660EAEQ37810200-3B72954A-A547-4D7D-917E-9B93C6EBE4B4Q37810228-A0280FE7-30CE-4C81-B6A8-A5FFC72A797AQ37857237-61CF427F-52D7-445C-8331-95E89C68062EQ37883742-DF5ADC1B-FE2C-4F77-82FC-412FC7D7CE95Q37893563-AC20190B-0ADA-4896-A894-AA1F67534763Q37944852-B347B014-48DE-4119-9218-48EA962FD6E0Q37970117-2573656C-5458-4C12-B974-5E83B6693B97Q37976444-C7BB5F3C-7A11-404B-BD22-FD8254452775Q38005438-8BC65114-BB81-4634-A7CB-478392CAA3C8Q38012171-FDED3974-CE5A-4885-9B93-536B7F83C60EQ38030883-90715299-8DD9-4D98-B468-44F3C0D38E96Q38066995-9F6067EC-984B-419A-9ECD-323B672FB8ABQ38071001-CF60523C-6A6C-4035-ADE2-870CBD168E7CQ38086175-9CCF95B6-DE54-4278-BB34-6E4C4F8F2F56Q38104574-5C496625-9CD3-4A0B-ACEB-8863682B8AFAQ38112324-7726B1DA-2388-4725-987E-813B7EF31D5BQ38267696-A883E071-ED9D-4F70-9793-27FCAD8E44CEQ38339664-5AC2314F-2F77-433D-9CC3-653126F66102Q38879333-AF4692B2-5137-49AA-9AAE-CAAEA8A67095Q39305815-6A0861EE-18CB-4919-9274-6FFA18A4281EQ40077940-6B823037-DF12-4B4A-90F8-8F3C8C7E8A59Q40562448-77F8B820-AA43-4D89-9204-C14DD2AC5DFB
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Analytical strategies for identifying drug metabolites.
@ast
Analytical strategies for identifying drug metabolites.
@en
type
label
Analytical strategies for identifying drug metabolites.
@ast
Analytical strategies for identifying drug metabolites.
@en
prefLabel
Analytical strategies for identifying drug metabolites.
@ast
Analytical strategies for identifying drug metabolites.
@en
P2093
P356
P1476
Analytical strategies for identifying drug metabolites.
@en
P2093
Angus Nedderman
Chandra Prakash
Christopher L Shaffer
P304
P356
10.1002/MAS.20128
P577
2007-05-01T00:00:00Z